“Upgrade” newsletter from Ian King, focuses on targeting 1,000% gains “on every single trade” in small cap stocks ($100 million to $3 billion) that are “disruptive.” Edited by Paul Mampilly until he left Banyan Hill in 2022.
Articles
- Most Relevant
- Most Recent
This is the intro from the ad we’re considering today: “Jim Rickards: Halfway to heaven, in a location with life-threatening temperatures, a little-known company is about to unleash… “‘God’s Gold’ “15 TIMES the concentration of the average global gold mine, this deposit contains arguably the highest-grade gold on the planet. “And one company trading for […]
A version of this article was originally published on October 21, 2019, but the ad continues to circulate and generate new questions so we have updated it to address any changes over the past six months. Hard to believe that the major publishers didn’t already have something called The Penny Stock Letter, but this is […]
Robert Morris is helming a biotech-focused stock newsletter that’s called Biotech Supertrader (modesty has no place in the world of newsletter promotions, of course), and I’ve never covered this letter before so I thought I ought to have a look at the latest teaser we’ve been asked about. Morris, incidentally, has been featured in our […]
[ed note: Michael Jorrin is not a doctor but we like to call him “Doc Gumshoe,” he writes non-investment pieces for us about medical hype and health issues from time to time — today he indulged me by taking on a pitch from a health newsletter that caught my eye] The promotional piece – endless […]
Introducing: Psychiatry Simplified[ed. note: This is an introductory piece from longtime reader Peter Tilton, who has proposed writing a regular column for Stock Gumshoe readers about psychiatry. Not an investing topic (though the behavior of many of us in the markets may well be something that’s in need of a diagnosis), but we thought you might find […]
[Ed note: if you’re new to Doc Gumshoe, this is our break from investment chatter: He’s our favorite medical writer and he shares his contrarian and thoughtful commentaries with us every now and again. Any opinions and assertions are his own.] It all starts with an unassailable truth: the healthier you are to start with, […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. His topics, words and opinions are his own. Enjoy!] It’s the second reel of conspiracy film Shooter, and Mark Wahlberg, whom government schemers are trying to frame for assassination, has just been shot twice. In the back of a stolen FBI car, […]
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and small revealing the unfortunate news that yet another promising agent for the treatment of AD has failed to meet its objectives in a […]
So, I’ve been following Aralez (ARLZ) for years. It’s my favorite drug trade. This company has a history of producing valuable drugs. Once they develop a drug, their strategy is to sell the licensing to other companies that produce and market the drugs, and pay ARLZ huge royalties with very attractive minimums, essentially make ARLZ […]
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]
[ed. note: We’ve been privileged to share with you some “non investment” commentary here from Michael Jorrin, a longtime medical writer who we like to call “Doc Gumshoe” — today he’s got a new piece for us that should help us think skeptically about yet more of the “easy solution” promises people make about health, […]
If you’ve had enough of James Altucher, well, I don’t blame you — he’s one of the more promotional guys out there right now in newsletterland, and his manic presentations get a little exhausting. Especially because Paradigm Press rarely provides the transcript option to let us see his words in black and white instead of […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] Readers not familiar with Stock Gumshoe usually arrive wondering if the salivation provoked by stock promotional writers for certain companies is justified. […]
Has anyone tried investing in Ourcrowd.com? I’ve been looking on the companies posted on their website, seems like minimum investment is $10,000. Most of this companies are startup. I’ve been planning to try investing on start up or pre IPO stocks. Anyone knows a better investment company or any tips on what good startup company […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]
The last time Doc Gumshoe surveyed the Alzheimer’s landscape, the most prominent feature was the FDA’s approval – misguided, I thought – of Biogen’s Aduhelm (aducanumab) and the consequences this would have for everybody’s Medicare B premium. Sure enough, on November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) confirmed the prediction that […]
We’ll start out with the COVID-19 news. Yes, we’re all sick and tired of all COVID-related matters, but it doesn’t much lift our spirits to ignore COVID and pretend that it’s well and truly gone. We know better. It still lurks, and even though case rates and hospitalization rates are way down, people we know […]
Previously thought about starting this thread based on population increase, scarcity and listening to Arch1 and HendrixNuzzles. So here it is. Share your best ideas, news, equities and thoughts. Best2All ~ Ben
Many folks have sent in this fun ad from the Oxford Club, one of many Agora-related publications — and a few folks even suggested the solution, which is easy if you’ve heard of it, but a bit obscure if you haven’t, and especially if you’ve never been a New Yorker. How’s that for a tease […]
Focuses on companies with hot new technologies, including biotech and technology stocks. Formerly run by Patrick Cox, who moved on to launch Transformational Technology Alert, a similar letter for Mauldin Economics, and Stephen Petranek and Gerald Celente have also briefly helmed this letter.
Stansberry & Associates’ Phase 1 Investor newsletter is teasing us about shares of a drug company: “On March 30, FDA results we’ve waited 2 years to receive could make you $195,600, overnight” — and they quote Porter Stansberry as saying that “This is the kind of situation that can change your life… where a $10,000 stake can allow you to literally quit work, forever.” Sounds nice, eh?
Louis Navellier started marketing his services late on Tuesday with an email that has the subject line: “Today’s Cut Takes us to the Brink!” In his words, “I have been telling my customers for several weeks now that this is the greatest buying opportunity of our lifetimes. But let me clarify: It’s not as simple as buying any old stock that’s cheap now, it’s about owning a mix of the highest quality stocks. That’s why I have spent the last few weeks creating what I call Action Plan For The Wipeout. Act today and you can put this plan to work for you, beat the market by over 3-to-1 AND be able to look at the morning news without flinching.”
What is his “Action Plan?” Read on for details!
Porter Stansberry, whose newsletters I write about from time to time, is revamping his new Porter Stansberry’s Put Strategy newsletter to focus not on his original plan — which was selling puts to buy bargains at even lower cost — but on betting on the demise of companies, and particularly (at the moment, at least) companies in commercial real estate.
And here’s the “tease” for the recent letter he sent out about this Put Strategy newsletter:
“America’s Next Major Bankruptcy (it’s not GM or CitiGroup)… Happens this FRIDAY at Midnight” —
What is this one?
A big part of the advertising that comes out for Carla Pasternak’s High Income Investing is by way of their writeups on the “income security of the month” — and, as she has done this month, she often recycles these ideas … it looks like today’s “Income Security of the Month” was also the income security of the Month for October.
Times are tough, everyone’s cutting back — so no need to hire another copywriter if you’ve got a perfectly good sales letter sitting around!
Some of the comments below first appeared in this space back then, which now seems a lifetime ago, but I’ve added some more info and done some updating.
“These special hybrid securities not only provide strong returns during market turmoil thanks to the ‘AAA’-rated portfolio of their parent company — they also provide unlimited upside potential since the shares are convertible at any time into stock of the underlying company.”
This month the temptation to buy, buy, buy is everywhere — at least, it is for an optimist, like me, who does not think we’re quite on the verge of another Great Depression. Stocks across almost every sector are historically cheap — that doesn’t mean they won’t get cheaper, but it may provide some comfort […]
I’ve been largely trying to hedge against catastrophic declines by using occasional options trades, usually buying put options (as I mentioned I’ve done with Vostok Nafta — to protect against the general downside in Russia I own puts against the RSX index, and have rolled over those puts to another expiration date, those puts, unfortunately, […]
Dan Amoss has added a new twist to the “100-F” teaser that I wrote about here a couple months ago, so I’m adding a new twist as well. He’s now calling this “Retirement Recovery Insurance,” and using examples of folks like laid-off auto workers who are using this strategy to make more money than they […]
OK, so my ancestry is mostly Swedish, and I can’t help but think of a smorgasbord when I see the latest email out from Louis Navellier for his Blue Chip Growth newsletter. If you don’t know what a smorgasbord is, it’s basically a big buffet layout of Swedish foods, often served at holidays. And like […]
When the world looks bleak, the skies darken, and the locusts appear to be swarming on CNBC, we can always count on one thing: Newsletter editors will be trying whatever they can to convince you that they see the way forward, or that they have a safe haven for your money. Karim Rahemtulla is no […]
This is just a quick note to let you know about part of what Martin Weiss is trying to sell you as part of a subscription to his Safe Money Report (now there’s a loaded name for a newsletter, eh?). He’s offering all kinds of stuff that’s designed to appeal to people who are terrified […]
If you’re not an analyst or asset manager who specializes in the financial sector, and you don’t count on AIG, Lehman Brothers, or their many near competitors for a paycheck, right now might be a good time to take a step back, breathe a little, and thank whatever deity or lucky totem you might carry, […]
I don’t write much about the various investment services available from Zack’s, simply because they don’t use teaser ads all that often (or at least, they don’t use fun ones that catch my interest). But one crossed my screen just today that I thought some of you might be interested in — it’s an ad […]
Today we have the pleasure of yet another ad that includes a made-up name that sounds official … This time, it’s the “100-F Document” — something that is filed in Washington, D.C. that will give you inside information into a company’s troubles, and let you bet against the company before it makes headlines. And it’s […]
Whole Foods Market, which has been pushed by the Motley Fool Stock Advisor as their favorite pick, and as the “New American Super Brand” for as long as I can remember (when I wrote about this ad over a year ago the first instance of it I could find was from December 2006, when the […]
I mentioned yesterday that I would be spending a little time running through the teaser stocks in Ann Sosnowski’s latest teaser ad for her Safe Haven Investor newsletter … so without further ado, here we go! This one is called the “Ultimate Recession Stock” in the ad, and whether or not you think we’re in […]
Most of us might not have heard of Georges Yared a year ago, but any individual investor with an email address will have a hard time avoiding him now — his is one of the latest investment newsletters launched by InvestorPlace Media, the folks who make sure we all know about newsletter advisers Robert Hsu, […]
This one is probably a few weeks old, going by the share price in the teaser, but it still might be interesting to folks … it is, at the very least, a truly unique investment. Good or bad, you can decide when you know the facts … but certainly unique. The teaser is from Yiannis […]
This delightful ad has clearly graced many an inbox over the past few days — I know I’ve gotten it about a dozen times myself, not to mention the hundreds of Gumshoe readers who have also been kind enough to send it along. OK, dozens. Still. So the marketing push is on … … but, […]